NeuroSense FDA Meeting Boosts ALS Trial and NDA Path
Ticker: NRSNW · Form: 6-K · Filed: Oct 28, 2024 · CIK: 1875091
Sentiment: bullish
Topics: FDA, ALS, clinical-trial, NDA
TL;DR
NeuroSense got a key FDA meeting for its ALS drug, moving closer to trial completion and NDA.
AI Summary
NeuroSense Therapeutics Ltd. announced on October 28, 2024, that it has secured a key meeting with the U.S. Food and Drug Administration (FDA). This meeting is crucial for advancing its Phase 3 Amyotrophic Lateral Sclerosis (ALS) trial and the subsequent New Drug Application (NDA) submission.
Why It Matters
This FDA meeting is a critical step towards potentially bringing a new treatment for ALS to market, offering hope to patients and impacting the pharmaceutical landscape.
Risk Assessment
Risk Level: medium — The company is still in the trial phase for its ALS drug, and FDA approval is not guaranteed.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Registrant
- U.S. Food and Drug Administration (FDA) (company) — Regulatory body
- October 28, 2024 (date) — Announcement date
- Amyotrophic Lateral Sclerosis (ALS) (medical_condition) — Disease being treated
FAQ
What is the purpose of the FDA meeting for NeuroSense Therapeutics?
The FDA meeting is to advance the company's Phase 3 ALS trial and its New Drug Application (NDA) submission.
What disease is NeuroSense Therapeutics targeting with its Phase 3 trial?
NeuroSense Therapeutics is targeting Amyotrophic Lateral Sclerosis (ALS) with its Phase 3 trial.
When was this information announced by NeuroSense Therapeutics?
The announcement was made on October 28, 2024.
What form was filed with the SEC regarding this announcement?
A Form 6-K was filed with the SEC, containing a press release as Exhibit 99.1.
What is the company's principal executive office address?
The company's principal executive office is located at 11 HaMenofim Street, Building B, Herzliya 4672562, Israel.
Filing Stats: 289 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2024-10-28 08:35:10
Filing Documents
- ea0218396-6k_neurosense.htm (6-K) — 11KB
- ea021839601ex99-1_neuro.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 14KB
- 0001213900-24-090982.txt ( ) — 49KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: October 28, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Office 2